1 Year of Palsonify and What Switching From Acromegaly Injections to a Pill Involves
Palsonify turns 1 on September 25th. A year of real-world data shows what trading monthly injections for a daily tablet actually involves, from the empty stomach rule to the $290,000 question insurers are mostly saying yes to.
We Built a Free Alpha-Gal Medication Checker
The FDA Approved a Drug for Your Rare Disease. When Do You Actually Get It?
When a Clinical Trial Fails and It Was Your Family's Trial
In the space of 6 days, Phase 3 trials failed in Angelman syndrome and myotonic dystrophy type 1, two diseases with no approved treatment. The coverage has been about stock prices. This is about the families who enrolled, what happens to them now, and what is honestly left to hope for.
The Median Rare Disease Trial Recruits at Exactly One US Site
What an FDA Clinical Hold Means When You're the One in the Trial
Zilurgisertib Could Give FOP Patients a Third Treatment on September 26th
FOP went centuries without a single approved treatment. Now the ultra-rare bone disease could see its third in barely 3 years when the FDA rules on zilurgisertib, a once-daily pill from Mirum and Incyte, on September 26th.
The State of Rare Disease Clinical Trials With 75% of 2026 Behind Us
4 Rare Diseases Could Get Their First Treatment This September
Sanfilippo Syndrome Could Get Its First Approved Treatment on September 19
On September 19, the FDA decides on UX111, a one-time gene therapy for Sanfilippo syndrome type A. No treatment has ever been approved for the disease. The science was never the FDA's objection, and the company behind it has already won two gene therapy approvals this year.
Opakalim, Azetukalner, and the Race to Bring Back Epilepsy's Lost Off Switch
A New AI Tool Called MARRVEL-MCP Is Changing the Slowest Part of Rare Disease Diagnosis
Rare Disease Diagnoses That Started With Something Else Entirely
Some of the most consequential rare disease diagnoses started with a routine carpal tunnel surgery, an unrelated CT scan, a yearly eye exam, or a young person's first stroke. This is a clinically documented guide to the incidental findings that have surfaced ATTR amyloidosis, Wilson disease, pheochromocytoma, Fabry disease, hereditary hemorrhagic telangiectasia, and other rare conditions years before symptoms made them obvious.
Lone Star Tick Bites and the Rare Diseases They Cause from Alpha-Gal Syndrome to Heartland Virus
Rystiggo for Myasthenia Gravis and How It Compares to Vyvgart and Imaavy
Alpha-Gal Syndrome: Medications, Vaccines, and Medical Products That Can Trigger a Reaction
Alpha-Gal Syndrome (AGS) is more than a red meat allergy. Heparin, certain monoclonal antibodies, gelatin in vaccines and capsules, surgical glues, and many over-the-counter medications can contain mammalian-derived alpha-gal and trigger a reaction. This is the comprehensive list of hidden alpha-gal exposures in healthcare, with the products to ask about, the safer alternatives, and what to tell every doctor before any procedure.
Casgevy vs. Lyfgenia: Comparing Sickle Cell Gene Therapies
School Accommodations for a Child with a Rare Disease: A Parent's Field Guide
hEDS, MCAS, POTS, MTHFR, and Tick-Borne Coinfections: When Rare Diagnoses Stack
Some rare disease patients walk into a specialist's office for one diagnosis and walk out, eventually, with 5. The hEDS / MCAS / POTS triad now has formal academic recognition. Layered with tick-borne coinfections and an MTHFR variant, it becomes one of the most complex and most missed presentations in medicine. What's solidly evidenced, what's still debated, and what patients can actually do.
Heparin-Induced Thrombocytopenia: A New Drug Path After 25 Years
Lonvo-Z and the First Phase 3 Win for In Vivo Gene Editing in HAE
Why Rare Disease Diagnoses Still Take 6 Years, and How Genome Sequencing Can Cut It to Weeks
A rare disease patient in the US waits 6 years on average for a diagnosis, accumulates 17 medical encounters, and gets 2 to 3 wrong answers along the way. A test that finds the genetic cause in 5 days now costs $100 to run. Most patients still don't get it. Here's what's blocking the path and how to push through.
The FDA's Plausible Mechanism Framework Could Unlock Gene Therapies for the Rarest Diseases
What Happens When You Take a Rare Disease to the ER
Ticks, Rare Disease, and the Coinfections Lyme Patients Have Been Told Don't Exist
The blacklegged tick carries at least 7 human pathogens. Three of them, babesiosis, bartonellosis, and anaplasmosis, are classified as rare diseases. Most doctors don't test for them. Here's what the science actually says.
How to Read a ClinicalTrials.gov Listing Without a Medical Degree
A Patient's Guide to Clinical Trial Participation
Most Clinical Trial Finders Are Recruitment Tools in Disguise. We Built Something Else.
Filspari Is the First FDA-Approved Treatment for FSGS. Here's What That Actually Means for Patients.
A Quiet Crisis in Rare Disease Research: Trial Enrollment Is Slowing Just as Treatments Start Working
Insurance Denied Your Medication. You Have More Power Than They Want You to Know.
When a rare disease drug gets denied by insurance, most patients give up. The data says they shouldn't. A practical guide to prior authorizations, appeals, external reviews, and the people who can help.
That Drug Your Child Takes? A Voucher Worth Millions Helped Make It Happen.
Avlayah Is the First New Hunter Syndrome Treatment in 20 Years. Here's What Families Should Do Next.
You Got Into a Clinical Trial. Now You Have to Get There.
The trial site is 4 hours away. Or a flight away. Your kid still has school. Your boss needs 2 weeks notice for time off. Nobody warned you about this part.
Dravet Syndrome Treatments in 2026: From Seizure Management to Gene Therapy
First Gene Therapy for BAG3 Heart Failure Enters Clinical Trials: What Patients Should Know
Tepezza Just Got a Major Upgrade: What the New At-Home Injection Means for Thyroid Eye Disease Patients
Amgen's Phase 3 trial showed that a subcutaneous version of Tepezza delivered via on-body injector matched the efficacy of the IV infusion, with a 77% proptosis response rate. For the roughly 25,000 patients managing TED in the U.S., this could replace 8 hospital infusions with 12 quick injections closer to home.
A New ALS Trial Is Recruiting and It Learned from What Came Before
84% of Investors Are Pulling Back from Rare Disease. Here Is Why That Should Alarm Every Patient.
From Zero Treatments to 5 in 3 Years: The IgA Nephropathy Breakthrough Nobody Saw Coming
Novartis just published 2-year Fabhalta data in the New England Journal of Medicine showing a 49.3% slowing of kidney function decline. Meanwhile, Biohaven's early-stage degrader program is producing results that could redefine how the disease is treated altogether. 3 years ago, IgAN patients had zero approved therapies.
Gene Therapy Pricing and Access: What Rare Disease Families Need to Know
What Happens After a Clinical Trial Ends - Your Options for Continued Access
A New Kind of MS Drug Just Cleared Its Biggest Hurdle: What Fenebrutinib Means for Patients
Roche's fenebrutinib hit its primary endpoint in all 3 Phase III trials, showing a 51-59% reduction in relapses for relapsing MS and the first new mechanism to slow disability in progressive MS in over a decade. Here is what that actually means if you or someone you know is living with MS.
One Baby Changed Everything: How the FDA Opened the Door for Ultra-Rare Disease Treatments
What Placebos and Randomization Actually Mean for You (In Plain English)
MECP2 Gene Therapy for Rett Syndrome: What Families Should Know About the Trials in 2026
Two gene therapy programs for Rett syndrome now have FDA Breakthrough Therapy designation and are in registrational or pivotal trials. For families weighing whether to pursue a trial, here is what the landscape actually looks like right now.
The Hidden Costs of Joining a Clinical Trial (And How to Get Help Paying for Them)
Regenxbio's Hunter Syndrome Gene Therapy Rejected: What Happened and What It Means
When the Measuring Stick Moves: Biohaven, the FDA, and What It Means for SCA Patients
Biohaven's SCA program hit a regulatory wall despite 8 years of FDA collaboration and data showing 70% slowing of disease progression. For patients losing coordination, speech, and independence with no approved treatments, the stakes could not be higher.